Breast cancer patients who carry the wild-type gene required for tamoxifen metabolism may have comparable risk of recurrence when taking tamoxifen or an aromatase inhibitor, according to modeling data. Cytochrome P450 2D6 (CYP2D6) converts tamoxifen into its metabolically active form called endoxifen.















Recent comments
24 weeks 4 days ago